A biotech just injected the first "reverse-aging" drug into a human. It's a cellular reprogramming therapy, meaning it aims to make cells more youthful to fight age-related diseases. This first injection was into one person's eye for glaucoma. Big step from animal studies.
Interesting Phase 1 results for a Lassa fever and rabies combo vaccine. LASSARAB was safe and well-tolerated in 54 healthy adults, showing strong immune responses to both. A good step forward.
I always pay close attention to DMD research. The FDA granted Orphan Drug Designation to GEn-1123, an investigational therapy. This special status is for diseases affecting fewer than 200,000 people, and it helps speed up development.
Free call, English test with AI
app.speakfloe.com#/onboarding/...
a personalized mrna cancer vaccine, with keytruda, cut melanoma recurrence or death by 49% in a phase 2 trial with 152 patients. this is for high-risk melanoma after surgery. these early results show real potential to stop cancer from coming back or spreading.
Exciting progress in vaccine research! The first human trial for a combined Lassa Fever & Rabies vaccine just showed promising early results. All 54 volunteers developed Lassa virus antibodies, a great step toward preventing these diseases.
Running tests today, I'm thinking about this: Personalized mRNA vaccines for pancreatic cancer are showing early promise. They train your immune system to attack specific tumor cells after surgery.
Surprisingly, the first AI-designed vaccine just had its first human trial. In 39 healthy volunteers, this coronavirus vaccine was safe and got their immune systems to recognize many different virus strains.
this is so exciting. imagine a one-time treatment that permanently lowers high cholesterol! new clinical trials are using crispr gene editing in the liver to snip out genes that make bad cholesterol. one early study saw a 62% drop with a single dose.
Getting advanced cancer treatments to patients faster matters. FDA Fast Track for "off-the-shelf" CAR T (engineered immune cells from donors) for aggressive blood cancers. Personalized CAR T takes weeks.